Selvita S.A.

Poland’s biopharma sector is best known for its strengths in generics and biosimilars, with companies like Polpharma SA providing central Europe and beyond with a reliable flow of affordable off-pat

Two highly anticipated initial public offerings finally launched on 10 October and landed at the low end of their proposed IPO price ranges, but both BioNTech SE and Vir Biotechnology Inc. are amo

In another move to build out its nascent pipeline, Singapore-based venture AUM Biosciences has acquired exclusive worldwide rights to a group of novel, multi-targeted kinase inhibitors from Inflection

Kraków, Poland-based Ryvu Therapeutics SA (formerly Selvita SA ) is to collaborate with Belgium biotech, Galapagos NV , on the discovery of small-molecule product candidates for the treatment of inf